Erythroleukemia: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 13: Line 13:
}}
}}
{{SI}}
{{SI}}
{{CMG}};  {{AE}}{{MA}} [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu]
{{CMG}};  {{AE}}{{MA}} [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu] [mailto:malihash@bidmc.harvard.edu]


{{SK}}Pure erythroid leukemia,  FAB ( French-American-British)  M6, acute erythroid leukemia, Di Guglielmo’s disease  
{{SK}}Pure erythroid leukemia,  FAB ( French-American-British)  M6, acute erythroid leukemia, Di Guglielmo’s disease  


==Overview==
==Overview==
Erythroleukemia was first discovered by M. Copelli, in 1912. In 1917, Di Guglielmo, Italian hematologist, described leukemic nature of the erythroleukemia. Erythroleukemia accounts for <5 percent of AML( acute myeloid leukemia). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The erythroid/myeloid type and the pure type. Erythroleukemia accounts for <5 percent of AML( acute myeloid leukemia). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The erythroid/myeloid type and the pure type. Erythroleukemia is a neoplastic proliferation of  myeloid and erythroid precursors of bone marrow hematopoietic stem cells. Erythroleukemia is accounting for 3–5% of all AML cases. Erythroleukemia may be caused by translocation t(1;16) generating the fusion gene NFIA/CBFA2T3. Erythroleukemia must be differentiated from MDS with erythroid predominanc, other types of AML with increased erythroid precursors, AML with myelodysplasia-related changes. The incidence of erythroleukemia is approximately 0.077 per 100,000 individuals worldwide. There are no established risk factors for de novo cases of erythroleukemia.
Erythroleukemia was first discovered by M. Copelli, in 1912. In 1917, Di Guglielmo, Italian hematologist, described leukemic nature of the erythroleukemia. Erythroleukemia accounts for <5 percent of [[AML]]( [[acute myeloid leukemia]]). Erythroleukemia may be classified according to previous version [[WHO]] into 2 subtypes : The [[erythroid]]/[[myeloid]] type and the pure type. Erythroleukemia accounts for <5 percent of [[AML]]( [[acute myeloid leukemia]]). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The [[erythroid]]/[[myeloid]] type and the pure type. Erythroleukemia is a [[neoplastic]] proliferation of  [[myeloid]] and [[erythroid]] precursors of [[bone marrow]] [[Hematopoietic stem cell|hematopoietic stem cells]]. Erythroleukemia is accounting for 3–5% of all [[AML]] cases. Erythroleukemia may be caused by [[Translocations|translocation]] t(1;16) generating the [[fusion gene]] NFIA/CBFA2T3. Erythroleukemia must be differentiated from [[Myelodysplastic syndrome|MDS]] with [[erythroid]] predominanc, other types of [[AML]] with increased [[erythroid]] precursors, [[AML]] with [[myelodysplasia]]-related changes. The [[incidence]] of erythroleukemia is approximately 0.077 per 100,000 individuals worldwide. There are no established risk factors for [[de novo]] cases of erythroleukemia.


The most potent risk factor in the development of secondary Erythroleukemia is previous MDS ( myelodysplastic syndrome). If left untreated, patients with Erythroleukemia may progress to develop bleeding due to [[disseminated intravascular coagulation]]. The diagnosis of Erythroleukemia (erythroid/myeloid type) is based on 20 percent or more blasts in bone marrow irrespective of the number of erythroid precursors. In pure erythroid leukemia, erythroblasts, at the stage of pronormoblast constitute more than 80 percent of the marrow cells. Symptoms include fatigue, easy brusing, abdominal pain, dyspnea. Physical examination of patients with Erythroleukemia may include hepatosplenomegaly, lymphadenpathy. Laboratory findings include pancytopenia and dysplastic PAS positive erythroblasts with overexpression of the multidrug resistance (MDR) gene product P-glycoprotein. Pharmacologic medical therapies for Erythroleukemia include Azacitidine and Decitabine. Allo-SCT ( Allogenic hematopoietic stem cell transplantation) is a good option for good candidtate.  
The most potent risk factor in the development of secondary Erythroleukemia is previous [[Myelodysplastic syndrome|MDS]] ( [[myelodysplastic syndrome]]). If left untreated, patients with Erythroleukemia may progress to develop bleeding due to [[disseminated intravascular coagulation]]. The diagnosis of Erythroleukemia ([[erythroid]]/[[myeloid]] type) is based on 20 percent or more [[Blast|blasts]] in [[bone marrow]] irrespective of the number of [[erythroid]] precursors. In pure erythroid leukemia, [[erythroblasts]], at the stage of [[pronormoblast]] constitute more than 80 percent of the marrow cells. Symptoms include fatigue, easy brusing, abdominal pain, [[dyspnea]]. Physical examination of patients with Erythroleukemia may include [[hepatosplenomegaly]], [[lymphadenopathy]]. Laboratory findings include [[pancytopenia]] and [[Dysplasia|dysplastic]] [[Periodic acid-Schiff stain|PAS]] positive [[erythroblasts]] with overexpression of the [[multidrug resistance]] ([[MDR]]) gene product [[P-glycoprotein]]. Pharmacologic medical therapies for Erythroleukemia include [[Azacytidine|Azacitidine]] and [[Decitabine]]. Allo-SCT ( Allogenic hematopoietic stem cell transplantation) is a good option for good candidtate.  
==Historical Perspective==
==Historical Perspective==
Erythroleukemia was first discovered by M. Copelli, in 1912.<ref name="pmid21091147">{{cite journal |vauthors=Santos FP, Bueso-Ramos CE, Ravandi F |title=Acute erythroleukemia: diagnosis and management |journal=Expert Rev Hematol |volume=3 |issue=6 |pages=705–18 |date=December 2010 |pmid=21091147 |doi=10.1586/ehm.10.62 |url=}}</ref>  
Erythroleukemia was first discovered by M. Copelli, in 1912.<ref name="pmid21091147">{{cite journal |vauthors=Santos FP, Bueso-Ramos CE, Ravandi F |title=Acute erythroleukemia: diagnosis and management |journal=Expert Rev Hematol |volume=3 |issue=6 |pages=705–18 |date=December 2010 |pmid=21091147 |doi=10.1586/ehm.10.62 |url=}}</ref>  


In 1917, Di Guglielmo, Italian hematologist, described leukemic nature of the erythroleukemia.  
In 1917, Di Guglielmo, Italian hematologist, described [[leukemic]] nature of the erythroleukemia.  


==Classification==
==Classification==
Erythroleukemia accounts for <5 percent of AML( acute myeloid leukemia). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The erythroid/myeloid type and the pure type.<ref name="pmid12752097">{{cite journal |vauthors=Forestier E, Heim S, Blennow E, Borgström G, Holmgren G, Heinonen K, Johannsson J, Kerndrup G, Andersen MK, Lundin C, Nordgren A, Rosenquist R, Swolin B, Johansson B |title=Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001 |journal=Br. J. Haematol. |volume=121 |issue=4 |pages=566–77 |date=May 2003 |pmid=12752097 |doi= |url=}}</ref>  
Erythroleukemia accounts for <5 percent of [[AML]]( [[acute myeloid leukemia]]). Erythroleukemia may be classified according to previous version [[WHO]] into 2 subtypes : The [[erythroid]]/[[myeloid]] type and the pure type.<ref name="pmid12752097">{{cite journal |vauthors=Forestier E, Heim S, Blennow E, Borgström G, Holmgren G, Heinonen K, Johannsson J, Kerndrup G, Andersen MK, Lundin C, Nordgren A, Rosenquist R, Swolin B, Johansson B |title=Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001 |journal=Br. J. Haematol. |volume=121 |issue=4 |pages=566–77 |date=May 2003 |pmid=12752097 |doi= |url=}}</ref>  


Diagnosis of erythroid/myeloid type, base on previous version WHO:  
Diagnosis of [[erythroid]]/[[myeloid]] type, base on previous version [[WHO]]:  
* Erythroid precursors more than 50 percent of the cells in bone marrow and,  
* [[Erythroid]] precursors more than 50 percent of the cells in [[bone marrow]] and,  
* The blasts compromise 20 percent or more of the non-erythroid cells
* The [[blast]]<nowiki/>s compromise 20 percent or more of the non-[[erythroid]] cells
2016 version of WHO calcification for AML (erythroid/myeloid type) :  
2016 version of WHO calcification for AML ([[erythroid]]/[[myeloid]] type) :  
* 20 percent or more blasts in bone marrow irrespective of the number of erythroid precursors
* 20 percent or more [[blast]]<nowiki/>s in bone marrow irrespective of the number of [[erythroid]] precursors
Diagnosis of pure erythroid leukemia:  
Diagnosis of pure [[erythroid]] [[leukemia]]:  
* Erythroblasts ( at the stage of pronormoblast >80 percent of the marrow cells in patients without exposure to cytotoxic agent and without AML genetic abnormalities). Erythroblasts may have vacuolization in the cytoplasm arrounding the nucleus ( pearl necklace).  
* [[Erythroblasts]] ( at the stage of [[Proerythroblast|pronormoblast]] >80 percent of the marrow cells in patients without exposure to [[cytotoxic]] agent and without [[AML]] [[genetic]] abnormalities). [[Erythroblasts]] may have [[vacuolization]] in the [[cytoplasm]] arrounding the [[nucleus]] ( pearl necklace).  


*  
*  


Erythroleukemia may be classified into 2 groups. De novo cases of erythroleukemia and secondary Erythroleukemia. De novo cases are not associated with any risk factors. The most common predisposing factors in secondary acute erythroleukemia is previous MDS ( myelodysplastic syndrome).  
Erythroleukemia may be classified into 2 groups. [[De novo]] cases of erythroleukemia and secondary Erythroleukemia. [[De novo]] cases are not associated with any [[Risk factor|risk factors]]. The most common predisposing factors in secondary acute erythroleukemia is previous [[MDS]] ( [[myelodysplastic syndrome]]).  


==Pathophysiology==
==Pathophysiology==
Erythroleukemia is a neoplastic proliferation of  myeloid and erythroid precursors of bone marrow hematopoietic stem cells. Erythroleukemia is accounting for 3–5% of all AML cases.<ref name="pmid210911472">{{cite journal |vauthors=Santos FP, Bueso-Ramos CE, Ravandi F |title=Acute erythroleukemia: diagnosis and management |journal=Expert Rev Hematol |volume=3 |issue=6 |pages=705–18 |date=December 2010 |pmid=21091147 |doi=10.1586/ehm.10.62 |url=}}</ref> A pure erythroid proliferation on rare occasion may occur.  The erythroblasts do not stain with MPO ( myeloperoxidase). Markers of myeloid lineage can not be expressed on the erythroblasts.''':'''   
Erythroleukemia is a [[neoplastic]] proliferation of  [[myeloid]] and [[erythroid]] precursors of [[bone marrow]] [[Hematopoietic stem cell|hematopoietic stem cells]]. Erythroleukemia is accounting for 3–5% of all [[AML]] cases.<ref name="pmid210911472">{{cite journal |vauthors=Santos FP, Bueso-Ramos CE, Ravandi F |title=Acute erythroleukemia: diagnosis and management |journal=Expert Rev Hematol |volume=3 |issue=6 |pages=705–18 |date=December 2010 |pmid=21091147 |doi=10.1586/ehm.10.62 |url=}}</ref> A pure [[erythroid]] proliferation on rare occasion may occur.  The [[erythroblasts]] do not stain with [[MPO]] ( [[myeloperoxidase]]). Markers of [[myeloid]] lineage can not be expressed on the [[erythroblasts]].''':'''   


'''Microscopic examanination:'''  
'''Microscopic examanination:'''  


Erythroblasts may have vacuolization in the cytoplasm arrounding the nucleus ( pearl necklace).   
[[Erythroblasts]] may have [[vacuolization]] in the [[cytoplasm]] arrounding the [[nucleus]] ( pearl necklace).   


'''Immunohistochemistry'''
'''Immunohistochemistry'''


Leukemic cells are positive for myeloid markers such as:<ref name="pmid2386768">{{cite journal |vauthors=Cuneo A, Van Orshoven A, Michaux JL, Boogaerts M, Louwagie A, Doyen C, Dal Cin P, Fagioli F, Castoldi G, Van den Berghe H |title=Morphologic, immunologic and cytogenetic studies in erythroleukaemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types |journal=Br. J. Haematol. |volume=75 |issue=3 |pages=346–54 |date=July 1990 |pmid=2386768 |doi= |url=}}</ref>
Leukemic cells are positive for [[myeloid]] markers such as:<ref name="pmid2386768">{{cite journal |vauthors=Cuneo A, Van Orshoven A, Michaux JL, Boogaerts M, Louwagie A, Doyen C, Dal Cin P, Fagioli F, Castoldi G, Van den Berghe H |title=Morphologic, immunologic and cytogenetic studies in erythroleukaemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types |journal=Br. J. Haematol. |volume=75 |issue=3 |pages=346–54 |date=July 1990 |pmid=2386768 |doi= |url=}}</ref>
* CD117
* [[CD117]]
* CD13
* [[CD13]]
* CD33
* [[CD33]]
* MPO (myeloperoxidase)
* [[MPO]] ([[myeloperoxidase]])
Megakaryocytes antigens can be positive in some cases of erythroleukemia:
[[Megakaryocyte|Megakaryocytes]] antigens can be positive in some cases of erythroleukemia:
* CD41  
* CD41  
* CD61
* [[CD61]]


==Causes==
==Causes==
Erythroleukemia may be caused by translocation t(1;16) generating the fusion gene NFIA/CBFA2T3. <ref name="pmid23032695">{{cite journal |vauthors=Micci F, Thorsen J, Panagopoulos I, Nyquist KB, Zeller B, Tierens A, Heim S |title=High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24) |journal=Leukemia |volume=27 |issue=4 |pages=980–2 |date=April 2013 |pmid=23032695 |pmc=3626019 |doi=10.1038/leu.2012.266 |url=}}</ref>
Erythroleukemia may be caused by [[translocation]] t(1;16) generating the [[fusion gene]] NFIA/CBFA2T3. <ref name="pmid23032695">{{cite journal |vauthors=Micci F, Thorsen J, Panagopoulos I, Nyquist KB, Zeller B, Tierens A, Heim S |title=High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24) |journal=Leukemia |volume=27 |issue=4 |pages=980–2 |date=April 2013 |pmid=23032695 |pmc=3626019 |doi=10.1038/leu.2012.266 |url=}}</ref>


==Differentiating Erythroleukemia from Other Diseases==
==Differentiating Erythroleukemia from Other Diseases==
Erythroleukemia must be differentiated from MDS with erythroid predominanc, other types of AML with increased erythroid precursors, AML with myelodysplasia-related changes. Nonneoplastic disorders that can cause erythroid predominance in the bone marrow such as megaloblastic anemia due to vitamin B12 or folate deficiency, heavy metal intoxication such as arsenic, drug effects (such as antineoplastic agents or chloramphenicol) are other differential diagnosis . <ref name="pmid208070442">{{cite journal |vauthors=Zuo Z, Polski JM, Kasyan A, Medeiros LJ |title=Acute erythroid leukemia |journal=Arch. Pathol. Lab. Med. |volume=134 |issue=9 |pages=1261–70 |date=September 2010 |pmid=20807044 |doi=10.1043/2009-0350-RA.1 |url=}}</ref>
Erythroleukemia must be differentiated from [[MDS]] with [[erythroid]] predominanc, other types of [[AML]] with increased [[erythroid]] precursors, [[AML]] with [[myelodysplasia]]-related changes. Nonneoplastic disorders that can cause [[erythroid]] predominance in the [[bone marrow]] such as [[megaloblastic anemia]] due to [[vitamin B12]] or [[folate]] deficiency, heavy metal [[intoxication]] such as [[arsenic]], drug effects (such as [[antineoplastic agents]] or [[chloramphenicol]]) are other differential diagnosis . <ref name="pmid208070442">{{cite journal |vauthors=Zuo Z, Polski JM, Kasyan A, Medeiros LJ |title=Acute erythroid leukemia |journal=Arch. Pathol. Lab. Med. |volume=134 |issue=9 |pages=1261–70 |date=September 2010 |pmid=20807044 |doi=10.1043/2009-0350-RA.1 |url=}}</ref>


==Epidemiology and Demographics==
==Epidemiology and Demographics==
The incidence of erythroleukemia is approximately 0.077 per 100,000 individuals worldwide. <ref name="pmid11477115">{{cite journal |vauthors=Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR |title=Erythroleukaemia in the north of England: a population based study |journal=J. Clin. Pathol. |volume=54 |issue=8 |pages=608–12 |date=August 2001 |pmid=11477115 |pmc=1731487 |doi= |url=}}</ref>
The [[incidence]] of erythroleukemia is approximately 0.077 per 100,000 individuals worldwide. <ref name="pmid11477115">{{cite journal |vauthors=Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR |title=Erythroleukaemia in the north of England: a population based study |journal=J. Clin. Pathol. |volume=54 |issue=8 |pages=608–12 |date=August 2001 |pmid=11477115 |pmc=1731487 |doi= |url=}}</ref>


Erythroleukemia commonly affects individuals older than 50 years of age with a median age of 65. <ref name="pmid210911473">{{cite journal |vauthors=Santos FP, Bueso-Ramos CE, Ravandi F |title=Acute erythroleukemia: diagnosis and management |journal=Expert Rev Hematol |volume=3 |issue=6 |pages=705–18 |date=December 2010 |pmid=21091147 |doi=10.1586/ehm.10.62 |url=}}</ref>
Erythroleukemia commonly affects individuals older than 50 years of age with a median age of 65. <ref name="pmid210911473">{{cite journal |vauthors=Santos FP, Bueso-Ramos CE, Ravandi F |title=Acute erythroleukemia: diagnosis and management |journal=Expert Rev Hematol |volume=3 |issue=6 |pages=705–18 |date=December 2010 |pmid=21091147 |doi=10.1586/ehm.10.62 |url=}}</ref>
Line 77: Line 77:


==Risk Factors==
==Risk Factors==
There are no established risk factors for de novo cases of erythroleukemia.  
There are no established risk factors for [[de novo]] cases of erythroleukemia.  


The most potent risk factor in the development of secondary Erythroleukemia is previous MDS ( myelodysplastic syndrome). <ref name="pmid1486289">{{cite journal |vauthors=Atkinson J, Hrisinko MA, Weil SC |title=Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature |journal=Blood Rev. |volume=6 |issue=4 |pages=204–14 |date=December 1992 |pmid=1486289 |doi= |url=}}</ref>  
The most potent risk factor in the development of secondary Erythroleukemia is previous [[MDS]] ( [[myelodysplastic syndrome]]). <ref name="pmid1486289">{{cite journal |vauthors=Atkinson J, Hrisinko MA, Weil SC |title=Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature |journal=Blood Rev. |volume=6 |issue=4 |pages=204–14 |date=December 1992 |pmid=1486289 |doi= |url=}}</ref>  


Other risk factors include:   
Other risk factors include:   
* Ionizing radiation such as Thorium dioxide suspension (Thorotrast)  
* [[Ionizing radiation]] such as [[Thorium dioxide]] suspension ([[Thorotrast]])  
* Previous use of chemotherapy drugs such as alkylating agents  
* Previous use of [[chemotherapy]] drugs such as [[Alkylating agent|alkylating]] agents  
* Famillial erythroleukemia, autosomal dominant disorder   
* Famillial erythroleukemia, autosomal dominant disorder   


==Screening==
==Screening==
There is insufficient evidence to recommend routine screening for Erythroleukemia.  
There is insufficient evidence to recommend routine [[screening]] for Erythroleukemia.  


==Natural History, Complications, and Prognosis==
==Natural History, Complications, and Prognosis==
If left untreated, patients with Erythroleukemia may progress to develop bleeding due to [[disseminated intravascular coagulation]].  
If left untreated, patients with Erythroleukemia may progress to develop [[bleeding]] due to [[disseminated intravascular coagulation]].  


Common complications of erythroleukemia include infection and bleeding. Therapy related complications are rash, c''ardiomyopathy and cerebellar toxicity.''
Common complications of erythroleukemia include [[infection]] and [[bleeding]]. Therapy related complications are [[rash]], [[Cardiomyopathy|c''ardiomyopathy'']] ''and [[cerebellar]] [[toxicity]].''


Prognosis is generally poor. 3-9 months after initial diagnosis is medican survival range. <ref name="pmid28420120">{{cite journal |vauthors=Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L |title=Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |journal=Int J Mol Sci |volume=18 |issue=4 |pages= |date=April 2017 |pmid=28420120 |pmc=5412421 |doi=10.3390/ijms18040837 |url=}}</ref> A high proerythroblast/myeloblast ratio correlates with worse outcome.<ref name="pmid17852448">{{cite journal |vauthors=Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S |title=Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify? |journal=Hematology |volume=12 |issue=5 |pages=381–5 |date=October 2007 |pmid=17852448 |doi=10.1080/10245330701393816 |url=}}</ref>
Prognosis is generally poor. 3-9 months after initial diagnosis is medican survival range. <ref name="pmid28420120">{{cite journal |vauthors=Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L |title=Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |journal=Int J Mol Sci |volume=18 |issue=4 |pages= |date=April 2017 |pmid=28420120 |pmc=5412421 |doi=10.3390/ijms18040837 |url=}}</ref> A high [[proerythroblast]]/[[myeloblast]] ratio correlates with worse outcome.<ref name="pmid17852448">{{cite journal |vauthors=Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S |title=Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify? |journal=Hematology |volume=12 |issue=5 |pages=381–5 |date=October 2007 |pmid=17852448 |doi=10.1080/10245330701393816 |url=}}</ref>


==Diagnosis==
==Diagnosis==
Line 100: Line 100:


===== Bone marrow biopsy =====
===== Bone marrow biopsy =====
The diagnosis of Erythroleukemia is based on 2016 version of WHO classification for AML:  
The diagnosis of Erythroleukemia is based on 2016 version of WHO classification for [[AML]]:  
* AML (erythroid/myeloid type): 20 percent or more blasts in bone marrow irrespective of the number of erythroid precursors
* [[AML]] ([[erythroid]]/[[myeloid]] type): 20 percent or more [[blast]]<nowiki/>s in [[bone marrow]] irrespective of the number of [[erythroid]] precursors
* Pure erythroid leukemia: Erythroblasts, at the stage of pronormoblast, more than 80 percent of the marrow cells in patients without exposure to cytotoxic agent and without AML genetic abnormalities. Erythroblasts may have vacuolization in the cytoplasm arrounding the nucleus ( pearl necklace).
* Pure erythroid leukemia: [[Erythroblasts]], at the stage of [[pronormoblast]], more than 80 percent of the [[marrow]] cells in patients without exposure to [[cytotoxic]] agent and without [[AML]] genetic abnormalities. [[Erythroblasts]] may have [[vacuolization]] in the [[cytoplasm]] arrounding the [[nucleus]] ( pearl necklace).


===History and Symptoms===
===History and Symptoms===
* Fatigue
* Fatigue
* Malaise
* [[Malaise]]
 
* Fatigue
* Malaise
* Bone pain
* Bone pain
* Abdominal pain
* [[Abdominal]] pain
* Weight loss
* Weight loss
* Easy bruising
* [[Easy bruising]]
* Fever
* [[Fever]]
* Dyspnea
* [[Dyspnea]]
Less common symptoms of Erythroleukemia include diffuse joint pain
Less common symptoms of Erythroleukemia include diffuse [[joint pain]].


===Physical Examination===
===Physical Examination===
Patients with Erythroleukemia usually appear anemic. Physical examination of patients with Erythroleukemia may include:<ref name="pmid20807044">{{cite journal |vauthors=Zuo Z, Polski JM, Kasyan A, Medeiros LJ |title=Acute erythroid leukemia |journal=Arch. Pathol. Lab. Med. |volume=134 |issue=9 |pages=1261–70 |date=September 2010 |pmid=20807044 |doi=10.1043/2009-0350-RA.1 |url=}}</ref>
Patients with Erythroleukemia usually appear [[anemic]]. Physical examination of patients with Erythroleukemia may include:<ref name="pmid20807044">{{cite journal |vauthors=Zuo Z, Polski JM, Kasyan A, Medeiros LJ |title=Acute erythroid leukemia |journal=Arch. Pathol. Lab. Med. |volume=134 |issue=9 |pages=1261–70 |date=September 2010 |pmid=20807044 |doi=10.1043/2009-0350-RA.1 |url=}}</ref>
* Ecchymoses or petechiae
* [[Ecchymoses]] or [[petechiae]]
* Hepatomegaly  
* [[Hepatomegaly]]
* Splenomegaly  
* [[Splenomegaly]]
* Lymphadenopathy
* [[Lymphadenopathy]]
* Headache
* [[Headache]]


===Laboratory Findings===
===Laboratory Findings===
* Pancytopenia<ref name="pmid26293512">{{cite journal |vauthors=Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA |title=Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response |journal=Leuk. Lymphoma |volume=57 |issue=4 |pages=812–9 |date=2016 |pmid=26293512 |doi=10.3109/10428194.2015.1079318 |url=}}</ref>
* [[Pancytopenia]]<ref name="pmid26293512">{{cite journal |vauthors=Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA |title=Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response |journal=Leuk. Lymphoma |volume=57 |issue=4 |pages=812–9 |date=2016 |pmid=26293512 |doi=10.3109/10428194.2015.1079318 |url=}}</ref>
* Few peripheral blood blasts<ref name="pmid16337853">{{cite journal |vauthors=Lessard M, Struski S, Leymarie V, Flandrin G, Lafage-Pochitaloff M, Mozziconacci MJ, Talmant P, Bastard C, Charrin C, Baranger L, Hélias C, Cornillet-Lefebvre P, Mugneret F, Cabrol C, Pagès MP, Fert-Ferret D, Nguyen-Khac F, Quilichini B, Barin C, Berger R |title=Cytogenetic study of 75 erythroleukemias |journal=Cancer Genet. Cytogenet. |volume=163 |issue=2 |pages=113–22 |date=December 2005 |pmid=16337853 |doi=10.1016/j.cancergencyto.2005.05.006 |url=}}</ref>
* Few peripheral blood [[blast]]<nowiki/>s<ref name="pmid16337853">{{cite journal |vauthors=Lessard M, Struski S, Leymarie V, Flandrin G, Lafage-Pochitaloff M, Mozziconacci MJ, Talmant P, Bastard C, Charrin C, Baranger L, Hélias C, Cornillet-Lefebvre P, Mugneret F, Cabrol C, Pagès MP, Fert-Ferret D, Nguyen-Khac F, Quilichini B, Barin C, Berger R |title=Cytogenetic study of 75 erythroleukemias |journal=Cancer Genet. Cytogenet. |volume=163 |issue=2 |pages=113–22 |date=December 2005 |pmid=16337853 |doi=10.1016/j.cancergencyto.2005.05.006 |url=}}</ref>
* Dysplasia in bone marrow and peripheral blood
* [[Dysplasia]] in [[bone marrow]] and [[peripheral blood]]
* Dysplastic PAS positive erythroblasts with overexpression of the multidrug resistance (MDR) gene product P-glycoprotein
* [[Dysplasia|Dysplastic]] [[PAS stain|PAS]] positive [[erythroblasts]] with overexpression of the [[multidrug resistance]] (MDR) gene product [[P-glycoprotein]]
* High freqiency of mutations, especially of TP53<ref name="pmid23648669">{{cite journal |vauthors=Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, Roller A, Eder C, Fasan A, Zenger M, Staller M, Kern W, Kohlmann A, Haferlach T |title=Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics |journal=Leukemia |volume=27 |issue=9 |pages=1940–3 |date=September 2013 |pmid=23648669 |doi=10.1038/leu.2013.144 |url=}}</ref>
* High freqiency of [[mutations]], especially of [[TP53]]<ref name="pmid23648669">{{cite journal |vauthors=Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, Roller A, Eder C, Fasan A, Zenger M, Staller M, Kern W, Kohlmann A, Haferlach T |title=Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics |journal=Leukemia |volume=27 |issue=9 |pages=1940–3 |date=September 2013 |pmid=23648669 |doi=10.1038/leu.2013.144 |url=}}</ref>


===Electrocardiogram===
===Electrocardiogram===
Electrocardiogram is useful for assessment of QT interval prior to starting chemptherapy. It is also useful for assessing arrhythmias induced by anthracycline chemotherapy. <ref name="pmid25616318">{{cite journal| author=Hefti E, Blanco JG| title=Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review. | journal=Cardiovasc Toxicol | year= 2016 | volume= 16 | issue= 1 | pages= 5-13 | pmid=25616318 | doi=10.1007/s12012-015-9307-1 | pmc=4514565 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25616318  }}</ref>For more information, click [[Acute myeloid leukemia electrocardiogram|here]].  
Electrocardiogram is useful for assessment of [[QT interval]] prior to starting [[chemotherapy]]. It is also useful for assessing [[arrhythmias]] induced by [[anthracycline]] [[chemotherapy]]. <ref name="pmid25616318">{{cite journal| author=Hefti E, Blanco JG| title=Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review. | journal=Cardiovasc Toxicol | year= 2016 | volume= 16 | issue= 1 | pages= 5-13 | pmid=25616318 | doi=10.1007/s12012-015-9307-1 | pmc=4514565 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25616318  }}</ref>For more information, click [[Acute myeloid leukemia electrocardiogram|here]].  


===X-ray===
===X-ray===
An x-ray may be helpful in the diagnosis of complications of Erythroleukemia management which include infection, volume overload. Chest  x-ray is also useful for venous catheter placement for chemotherapy.  
An [[x-ray]] may be helpful in the diagnosis of complications of Erythroleukemia management which include [[infection]], volume overload. [[Chest X-ray|Chest  x-ray]] is also useful for [[venous]] [[catheter]] placement for [[chemotherapy]].  


===Echocardiography or Ultrasound===
===Echocardiography or Ultrasound===
An echocardiogram is helpful for assessing cardiac function ( ejection fraction) in patients with acute myeloid leukemia before and after receiving anthracycline chemotherapy. <ref name="pmid24947931">{{cite journal |vauthors=Armenian SH, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S |title=Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors |journal=Clin. Cancer Res. |volume=20 |issue=24 |pages=6314–23 |date=December 2014 |pmid=24947931 |pmc=4268342 |doi=10.1158/1078-0432.CCR-13-3490 |url=}}</ref>
An [[echocardiogram]] is helpful for assessing [[cardiac]] function ( [[ejection fraction]]) in patients with [[acute myeloid leukemia]] before and after receiving [[anthracycline]] [[chemotherapy]]. <ref name="pmid24947931">{{cite journal |vauthors=Armenian SH, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S |title=Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors |journal=Clin. Cancer Res. |volume=20 |issue=24 |pages=6314–23 |date=December 2014 |pmid=24947931 |pmc=4268342 |doi=10.1158/1078-0432.CCR-13-3490 |url=}}</ref>


An ultrasound is useful for diagnosis of lower extremity thrombosis, which commonly occurs in patients with acute myeloid leukemia.<ref name="pmid20124617">{{cite journal |vauthors=Oehadian A, Iqbal M, Sumantri R |title=Deep vein thrombosis in acute myelogenous leukemia |journal=Acta Med Indones |volume=41 |issue=4 |pages=200–4 |date=October 2009 |pmid=20124617 |doi= |url=}}</ref>
An [[ultrasound]] is useful for diagnosis of [[lower extremity]] [[thrombosis]], which commonly occurs in patients with [[acute myeloid leukemia]].<ref name="pmid20124617">{{cite journal |vauthors=Oehadian A, Iqbal M, Sumantri R |title=Deep vein thrombosis in acute myelogenous leukemia |journal=Acta Med Indones |volume=41 |issue=4 |pages=200–4 |date=October 2009 |pmid=20124617 |doi= |url=}}</ref>


===CT scan===
===CT scan===
Abdominal and chest CT scan may be helpful in the diagnosis of acute myeloid leukemia. Findings on CT scan suggestive of of acute myeloid leukemia include lymphadenopathy, hepatomegaly, splenomegaly and pulmonary embolism because of deep venous thrombosis. <ref name="pmid27642861">{{cite journal |vauthors=Vallipuram J, Dhalla S, Bell CM, Dresser L, Han H, Husain S, Minden MD, Paul NS, So M, Steinberg M, Vallipuram M, Wong G, Morris AM |title=Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia |journal=Leuk. Lymphoma |volume=58 |issue=4 |pages=834–841 |date=April 2017 |pmid=27642861 |doi=10.1080/10428194.2016.1213825 |url=}}</ref>
[[Abdominal]] and [[chest]] CT scan may be helpful in the diagnosis of [[acute myeloid leukemia]]. Findings on [[CT scan]] suggestive of [[acute myeloid leukemia]] include [[lymphadenopathy]], [[hepatomegaly]], [[splenomegaly]] and [[pulmonary embolism]] because of [[Deep vein thrombosis|deep venous thrombosis]]. <ref name="pmid27642861">{{cite journal |vauthors=Vallipuram J, Dhalla S, Bell CM, Dresser L, Han H, Husain S, Minden MD, Paul NS, So M, Steinberg M, Vallipuram M, Wong G, Morris AM |title=Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia |journal=Leuk. Lymphoma |volume=58 |issue=4 |pages=834–841 |date=April 2017 |pmid=27642861 |doi=10.1080/10428194.2016.1213825 |url=}}</ref>


Non contrast brain CT scan is useful to rule out CNS bleed.<ref name="pmid22931433">{{cite journal |vauthors=Chen CY, Tai CH, Cheng A, Wu HC, Tsay W, Liu JH, Chen PY, Huang SY, Yao M, Tang JL, Tien HF |title=Intracranial hemorrhage in adult patients with hematological malignancies |journal=BMC Med |volume=10 |issue= |pages=97 |date=August 2012 |pmid=22931433 |pmc=3482556 |doi=10.1186/1741-7015-10-97 |url=}}</ref>
Non [[contrast]] brain [[CT scan]] is useful to rule out [[CNS]] bleed.<ref name="pmid22931433">{{cite journal |vauthors=Chen CY, Tai CH, Cheng A, Wu HC, Tsay W, Liu JH, Chen PY, Huang SY, Yao M, Tang JL, Tien HF |title=Intracranial hemorrhage in adult patients with hematological malignancies |journal=BMC Med |volume=10 |issue= |pages=97 |date=August 2012 |pmid=22931433 |pmc=3482556 |doi=10.1186/1741-7015-10-97 |url=}}</ref>


===MRI===
===MRI===
Brain MRI is helpful in the diagnosis of CNS bleeding in acute myeloid leukemia. <ref name="pmid26239467">{{cite journal |vauthors=Cervantes GM, Cayci Z |title=Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author's Institution |journal=J Clin Med |volume=4 |issue=5 |pages=1102–12 |date=May 2015 |pmid=26239467 |pmc=4470219 |doi=10.3390/jcm4051102 |url=}}</ref>
Brain [[MRI]] is helpful in the diagnosis of [[CNS]] bleeding in [[acute myeloid leukemia]]. <ref name="pmid26239467">{{cite journal |vauthors=Cervantes GM, Cayci Z |title=Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author's Institution |journal=J Clin Med |volume=4 |issue=5 |pages=1102–12 |date=May 2015 |pmid=26239467 |pmc=4470219 |doi=10.3390/jcm4051102 |url=}}</ref>


===Other Imaging Findings===
===Other Imaging Findings===
Line 158: Line 155:


===== Flow cytometry: =====
===== Flow cytometry: =====
The myeloid blasts are often postive for myeloid marker such as CD117, CD13, CD33 and MPO.<ref name="pmid21393910">{{cite journal |vauthors=Sharma A, Buxi G, Walia R, Yadav RB, Sharma S |title=Childhood acute erythroleukemia diagnosis by flow cytometry |journal=Indian J Pathol Microbiol |volume=54 |issue=1 |pages=173–5 |date=2011 |pmid=21393910 |doi=10.4103/0377-4929.77395 |url=}}</ref>
The [[myeloid]] [[blast]]<nowiki/>s are often postive for [[myeloid]] marker such as [[CD117]], [[CD13]], [[CD33]] and [[Myeloperoxidase|MPO]].<ref name="pmid21393910">{{cite journal |vauthors=Sharma A, Buxi G, Walia R, Yadav RB, Sharma S |title=Childhood acute erythroleukemia diagnosis by flow cytometry |journal=Indian J Pathol Microbiol |volume=54 |issue=1 |pages=173–5 |date=2011 |pmid=21393910 |doi=10.4103/0377-4929.77395 |url=}}</ref>


The erythroblasts lack myeloid antigens. They are postive for glycophorin A.   
The [[erythroblasts]] lack [[myeloid]] antigens. They are postive for glycophorin A.   


===== Cytogenetics: =====
===== Cytogenetics: =====
Loss of all or part of the long arm (q) of chromosomes 5 and/or 7. <ref name="pmid14862892">{{cite journal |vauthors=Atkinson J, Hrisinko MA, Weil SC |title=Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature |journal=Blood Rev. |volume=6 |issue=4 |pages=204–14 |date=December 1992 |pmid=1486289 |doi= |url=}}</ref>
Loss of all or part of the long arm (q) of [[Chromosome|chromosomes]] 5 and/or 7. <ref name="pmid14862892">{{cite journal |vauthors=Atkinson J, Hrisinko MA, Weil SC |title=Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature |journal=Blood Rev. |volume=6 |issue=4 |pages=204–14 |date=December 1992 |pmid=1486289 |doi= |url=}}</ref>


==Treatment==
==Treatment==
===Medical Therapy===
===Medical Therapy===
Pharmacologic medical therapy is recommended among patients with Erythroleukemia who are not candidate for intensive chemotherapy or allogenic hematopoietic stem cell transplantation. <ref name="pmid284201202">{{cite journal |vauthors=Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L |title=Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |journal=Int J Mol Sci |volume=18 |issue=4 |pages= |date=April 2017 |pmid=28420120 |pmc=5412421 |doi=10.3390/ijms18040837 |url=}}</ref>
Pharmacologic medical therapy is recommended among patients with Erythroleukemia who are not candidate for intensive [[chemotherapy]] or allogenic hematopoietic stem cell transplantation. <ref name="pmid284201202">{{cite journal |vauthors=Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L |title=Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study |journal=Int J Mol Sci |volume=18 |issue=4 |pages= |date=April 2017 |pmid=28420120 |pmc=5412421 |doi=10.3390/ijms18040837 |url=}}</ref>


Pharmacologic medical therapies for Erythroleukemia include hyypomethylating agents ( HMA) such as:<ref name="pmid20026804">{{cite journal |vauthors=Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR |title=Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia |journal=J. Clin. Oncol. |volume=28 |issue=4 |pages=562–9 |date=February 2010 |pmid=20026804 |doi=10.1200/JCO.2009.23.8329 |url=}}</ref>
Pharmacologic medical therapies for Erythroleukemia include hypomethylating agents ( HMA) such as:<ref name="pmid20026804">{{cite journal |vauthors=Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR |title=Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia |journal=J. Clin. Oncol. |volume=28 |issue=4 |pages=562–9 |date=February 2010 |pmid=20026804 |doi=10.1200/JCO.2009.23.8329 |url=}}</ref>
* Azacitidine
* [[Azacytidine|Azacitidine]]
* Decitabine
* [[Decitabine]]
For more information about acute myeloid leukemia medical therapy, click [[Acute myeloid leukemia medical therapy|here]].
For more information about acute myeloid leukemia medical therapy, click [[Acute myeloid leukemia medical therapy|here]].


===Surgery===
===Surgery===
* Allo-SCT ( Allogenic hematopoietic stem cell transplantation)<ref name="pmid284201202" />
* Allo-SCT ( Allogenic hematopoietic stem cell transplantation)<ref name="pmid284201202" />
.


===Primary Prevention===
===Primary Prevention===

Revision as of 03:08, 13 December 2018

Template:DiseaseDisorder infobox

WikiDoc Resources for Erythroleukemia

Articles

Most recent articles on Erythroleukemia

Most cited articles on Erythroleukemia

Review articles on Erythroleukemia

Articles on Erythroleukemia in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Erythroleukemia

Images of Erythroleukemia

Photos of Erythroleukemia

Podcasts & MP3s on Erythroleukemia

Videos on Erythroleukemia

Evidence Based Medicine

Cochrane Collaboration on Erythroleukemia

Bandolier on Erythroleukemia

TRIP on Erythroleukemia

Clinical Trials

Ongoing Trials on Erythroleukemia at Clinical Trials.gov

Trial results on Erythroleukemia

Clinical Trials on Erythroleukemia at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erythroleukemia

NICE Guidance on Erythroleukemia

NHS PRODIGY Guidance

FDA on Erythroleukemia

CDC on Erythroleukemia

Books

Books on Erythroleukemia

News

Erythroleukemia in the news

Be alerted to news on Erythroleukemia

News trends on Erythroleukemia

Commentary

Blogs on Erythroleukemia

Definitions

Definitions of Erythroleukemia

Patient Resources / Community

Patient resources on Erythroleukemia

Discussion groups on Erythroleukemia

Patient Handouts on Erythroleukemia

Directions to Hospitals Treating Erythroleukemia

Risk calculators and risk factors for Erythroleukemia

Healthcare Provider Resources

Symptoms of Erythroleukemia

Causes & Risk Factors for Erythroleukemia

Diagnostic studies for Erythroleukemia

Treatment of Erythroleukemia

Continuing Medical Education (CME)

CME Programs on Erythroleukemia

International

Erythroleukemia en Espanol

Erythroleukemia en Francais

Business

Erythroleukemia in the Marketplace

Patents on Erythroleukemia

Experimental / Informatics

List of terms related to Erythroleukemia

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mahda Alihashemi M.D. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12]

Synonyms and keywords:Pure erythroid leukemia, FAB ( French-American-British) M6, acute erythroid leukemia, Di Guglielmo’s disease

Overview

Erythroleukemia was first discovered by M. Copelli, in 1912. In 1917, Di Guglielmo, Italian hematologist, described leukemic nature of the erythroleukemia. Erythroleukemia accounts for <5 percent of AML( acute myeloid leukemia). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The erythroid/myeloid type and the pure type. Erythroleukemia accounts for <5 percent of AML( acute myeloid leukemia). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The erythroid/myeloid type and the pure type. Erythroleukemia is a neoplastic proliferation of myeloid and erythroid precursors of bone marrow hematopoietic stem cells. Erythroleukemia is accounting for 3–5% of all AML cases. Erythroleukemia may be caused by translocation t(1;16) generating the fusion gene NFIA/CBFA2T3. Erythroleukemia must be differentiated from MDS with erythroid predominanc, other types of AML with increased erythroid precursors, AML with myelodysplasia-related changes. The incidence of erythroleukemia is approximately 0.077 per 100,000 individuals worldwide. There are no established risk factors for de novo cases of erythroleukemia.

The most potent risk factor in the development of secondary Erythroleukemia is previous MDS ( myelodysplastic syndrome). If left untreated, patients with Erythroleukemia may progress to develop bleeding due to disseminated intravascular coagulation. The diagnosis of Erythroleukemia (erythroid/myeloid type) is based on 20 percent or more blasts in bone marrow irrespective of the number of erythroid precursors. In pure erythroid leukemia, erythroblasts, at the stage of pronormoblast constitute more than 80 percent of the marrow cells. Symptoms include fatigue, easy brusing, abdominal pain, dyspnea. Physical examination of patients with Erythroleukemia may include hepatosplenomegaly, lymphadenopathy. Laboratory findings include pancytopenia and dysplastic PAS positive erythroblasts with overexpression of the multidrug resistance (MDR) gene product P-glycoprotein. Pharmacologic medical therapies for Erythroleukemia include Azacitidine and Decitabine. Allo-SCT ( Allogenic hematopoietic stem cell transplantation) is a good option for good candidtate.

Historical Perspective

Erythroleukemia was first discovered by M. Copelli, in 1912.[1]

In 1917, Di Guglielmo, Italian hematologist, described leukemic nature of the erythroleukemia.

Classification

Erythroleukemia accounts for <5 percent of AML( acute myeloid leukemia). Erythroleukemia may be classified according to previous version WHO into 2 subtypes : The erythroid/myeloid type and the pure type.[2]

Diagnosis of erythroid/myeloid type, base on previous version WHO:

2016 version of WHO calcification for AML (erythroid/myeloid type) :

  • 20 percent or more blasts in bone marrow irrespective of the number of erythroid precursors

Diagnosis of pure erythroid leukemia:

Erythroleukemia may be classified into 2 groups. De novo cases of erythroleukemia and secondary Erythroleukemia. De novo cases are not associated with any risk factors. The most common predisposing factors in secondary acute erythroleukemia is previous MDS ( myelodysplastic syndrome).

Pathophysiology

Erythroleukemia is a neoplastic proliferation of myeloid and erythroid precursors of bone marrow hematopoietic stem cells. Erythroleukemia is accounting for 3–5% of all AML cases.[3] A pure erythroid proliferation on rare occasion may occur. The erythroblasts do not stain with MPO ( myeloperoxidase). Markers of myeloid lineage can not be expressed on the erythroblasts.:

Microscopic examanination:

Erythroblasts may have vacuolization in the cytoplasm arrounding the nucleus ( pearl necklace).

Immunohistochemistry

Leukemic cells are positive for myeloid markers such as:[4]

Megakaryocytes antigens can be positive in some cases of erythroleukemia:

Causes

Erythroleukemia may be caused by translocation t(1;16) generating the fusion gene NFIA/CBFA2T3. [5]

Differentiating Erythroleukemia from Other Diseases

Erythroleukemia must be differentiated from MDS with erythroid predominanc, other types of AML with increased erythroid precursors, AML with myelodysplasia-related changes. Nonneoplastic disorders that can cause erythroid predominance in the bone marrow such as megaloblastic anemia due to vitamin B12 or folate deficiency, heavy metal intoxication such as arsenic, drug effects (such as antineoplastic agents or chloramphenicol) are other differential diagnosis . [6]

Epidemiology and Demographics

The incidence of erythroleukemia is approximately 0.077 per 100,000 individuals worldwide. [7]

Erythroleukemia commonly affects individuals older than 50 years of age with a median age of 65. [8]

There is no racial predilection to Erythroleukemia.

Men are more affected by Erythroleukemia than women. (male to female ratio = 2:1)


Risk Factors

There are no established risk factors for de novo cases of erythroleukemia.

The most potent risk factor in the development of secondary Erythroleukemia is previous MDS ( myelodysplastic syndrome). [9]

Other risk factors include:

Screening

There is insufficient evidence to recommend routine screening for Erythroleukemia.

Natural History, Complications, and Prognosis

If left untreated, patients with Erythroleukemia may progress to develop bleeding due to disseminated intravascular coagulation.

Common complications of erythroleukemia include infection and bleeding. Therapy related complications are rash, cardiomyopathy and cerebellar toxicity.

Prognosis is generally poor. 3-9 months after initial diagnosis is medican survival range. [10] A high proerythroblast/myeloblast ratio correlates with worse outcome.[11]

Diagnosis

Diagnostic Study of Choice

Bone marrow biopsy

The diagnosis of Erythroleukemia is based on 2016 version of WHO classification for AML:

History and Symptoms

Less common symptoms of Erythroleukemia include diffuse joint pain.

Physical Examination

Patients with Erythroleukemia usually appear anemic. Physical examination of patients with Erythroleukemia may include:[12]

Laboratory Findings

Electrocardiogram

Electrocardiogram is useful for assessment of QT interval prior to starting chemotherapy. It is also useful for assessing arrhythmias induced by anthracycline chemotherapy. [16]For more information, click here.

X-ray

An x-ray may be helpful in the diagnosis of complications of Erythroleukemia management which include infection, volume overload. Chest x-ray is also useful for venous catheter placement for chemotherapy.

Echocardiography or Ultrasound

An echocardiogram is helpful for assessing cardiac function ( ejection fraction) in patients with acute myeloid leukemia before and after receiving anthracycline chemotherapy. [17]

An ultrasound is useful for diagnosis of lower extremity thrombosis, which commonly occurs in patients with acute myeloid leukemia.[18]

CT scan

Abdominal and chest CT scan may be helpful in the diagnosis of acute myeloid leukemia. Findings on CT scan suggestive of acute myeloid leukemia include lymphadenopathy, hepatomegaly, splenomegaly and pulmonary embolism because of deep venous thrombosis. [19]

Non contrast brain CT scan is useful to rule out CNS bleed.[20]

MRI

Brain MRI is helpful in the diagnosis of CNS bleeding in acute myeloid leukemia. [21]

Other Imaging Findings

There are no other imaging findings associated with Erythroleukemia.

Other Diagnostic Studies

Flow cytometry:

The myeloid blasts are often postive for myeloid marker such as CD117, CD13, CD33 and MPO.[22]

The erythroblasts lack myeloid antigens. They are postive for glycophorin A.

Cytogenetics:

Loss of all or part of the long arm (q) of chromosomes 5 and/or 7. [23]

Treatment

Medical Therapy

Pharmacologic medical therapy is recommended among patients with Erythroleukemia who are not candidate for intensive chemotherapy or allogenic hematopoietic stem cell transplantation. [24]

Pharmacologic medical therapies for Erythroleukemia include hypomethylating agents ( HMA) such as:[25]

For more information about acute myeloid leukemia medical therapy, click here.

Surgery

  • Allo-SCT ( Allogenic hematopoietic stem cell transplantation)[24]

Primary Prevention

There are no established measures for the primary prevention of Erythroleukemia.

Secondary Prevention

Effective measures for the secondary prevention of Erythroleukemia include maintenance of remission treatment posttransplant.[26]

References

  1. ↑ Santos FP, Bueso-Ramos CE, Ravandi F (December 2010). "Acute erythroleukemia: diagnosis and management". Expert Rev Hematol. 3 (6): 705–18. doi:10.1586/ehm.10.62. PMID 21091147.
  2. ↑ Forestier E, Heim S, Blennow E, Borgström G, Holmgren G, Heinonen K, Johannsson J, Kerndrup G, Andersen MK, Lundin C, Nordgren A, Rosenquist R, Swolin B, Johansson B (May 2003). "Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001". Br. J. Haematol. 121 (4): 566–77. PMID 12752097.
  3. ↑ Santos FP, Bueso-Ramos CE, Ravandi F (December 2010). "Acute erythroleukemia: diagnosis and management". Expert Rev Hematol. 3 (6): 705–18. doi:10.1586/ehm.10.62. PMID 21091147.
  4. ↑ Cuneo A, Van Orshoven A, Michaux JL, Boogaerts M, Louwagie A, Doyen C, Dal Cin P, Fagioli F, Castoldi G, Van den Berghe H (July 1990). "Morphologic, immunologic and cytogenetic studies in erythroleukaemia: evidence for multilineage involvement and identification of two distinct cytogenetic-clinicopathological types". Br. J. Haematol. 75 (3): 346–54. PMID 2386768.
  5. ↑ Micci F, Thorsen J, Panagopoulos I, Nyquist KB, Zeller B, Tierens A, Heim S (April 2013). "High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24)". Leukemia. 27 (4): 980–2. doi:10.1038/leu.2012.266. PMC 3626019. PMID 23032695.
  6. ↑ Zuo Z, Polski JM, Kasyan A, Medeiros LJ (September 2010). "Acute erythroid leukemia". Arch. Pathol. Lab. Med. 134 (9): 1261–70. doi:10.1043/2009-0350-RA.1. PMID 20807044.
  7. ↑ Wells AW, Bown N, Reid MM, Hamilton PJ, Jackson GH, Taylor PR (August 2001). "Erythroleukaemia in the north of England: a population based study". J. Clin. Pathol. 54 (8): 608–12. PMC 1731487. PMID 11477115.
  8. ↑ Santos FP, Bueso-Ramos CE, Ravandi F (December 2010). "Acute erythroleukemia: diagnosis and management". Expert Rev Hematol. 3 (6): 705–18. doi:10.1586/ehm.10.62. PMID 21091147.
  9. ↑ Atkinson J, Hrisinko MA, Weil SC (December 1992). "Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature". Blood Rev. 6 (4): 204–14. PMID 1486289.
  10. ↑ Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L (April 2017). "Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study". Int J Mol Sci. 18 (4). doi:10.3390/ijms18040837. PMC 5412421. PMID 28420120.
  11. ↑ Srinivas U, Kumar R, Pati H, Saxena R, Tyagi S (October 2007). "Sub classification and clinico-hematological correlation of 40 cases of acute erythroleukemia - can proerythroblast/myeloblast and proerythroblast/total erythroid cell ratios help subclassify?". Hematology. 12 (5): 381–5. doi:10.1080/10245330701393816. PMID 17852448.
  12. ↑ Zuo Z, Polski JM, Kasyan A, Medeiros LJ (September 2010). "Acute erythroid leukemia". Arch. Pathol. Lab. Med. 134 (9): 1261–70. doi:10.1043/2009-0350-RA.1. PMID 20807044.
  13. ↑ Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA (2016). "Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response". Leuk. Lymphoma. 57 (4): 812–9. doi:10.3109/10428194.2015.1079318. PMID 26293512.
  14. ↑ Lessard M, Struski S, Leymarie V, Flandrin G, Lafage-Pochitaloff M, Mozziconacci MJ, Talmant P, Bastard C, Charrin C, Baranger L, Hélias C, Cornillet-Lefebvre P, Mugneret F, Cabrol C, Pagès MP, Fert-Ferret D, Nguyen-Khac F, Quilichini B, Barin C, Berger R (December 2005). "Cytogenetic study of 75 erythroleukemias". Cancer Genet. Cytogenet. 163 (2): 113–22. doi:10.1016/j.cancergencyto.2005.05.006. PMID 16337853.
  15. ↑ Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, Roller A, Eder C, Fasan A, Zenger M, Staller M, Kern W, Kohlmann A, Haferlach T (September 2013). "Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics". Leukemia. 27 (9): 1940–3. doi:10.1038/leu.2013.144. PMID 23648669.
  16. ↑ Hefti E, Blanco JG (2016). "Anthracycline-Related Cardiotoxicity in Patients with Acute Myeloid Leukemia and Down Syndrome: A Literature Review". Cardiovasc Toxicol. 16 (1): 5–13. doi:10.1007/s12012-015-9307-1. PMC 4514565. PMID 25616318.
  17. ↑ Armenian SH, Gelehrter SK, Vase T, Venkatramani R, Landier W, Wilson KD, Herrera C, Reichman L, Menteer JD, Mascarenhas L, Freyer DR, Venkataraman K, Bhatia S (December 2014). "Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors". Clin. Cancer Res. 20 (24): 6314–23. doi:10.1158/1078-0432.CCR-13-3490. PMC 4268342. PMID 24947931.
  18. ↑ Oehadian A, Iqbal M, Sumantri R (October 2009). "Deep vein thrombosis in acute myelogenous leukemia". Acta Med Indones. 41 (4): 200–4. PMID 20124617.
  19. ↑ Vallipuram J, Dhalla S, Bell CM, Dresser L, Han H, Husain S, Minden MD, Paul NS, So M, Steinberg M, Vallipuram M, Wong G, Morris AM (April 2017). "Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia". Leuk. Lymphoma. 58 (4): 834–841. doi:10.1080/10428194.2016.1213825. PMID 27642861.
  20. ↑ Chen CY, Tai CH, Cheng A, Wu HC, Tsay W, Liu JH, Chen PY, Huang SY, Yao M, Tang JL, Tien HF (August 2012). "Intracranial hemorrhage in adult patients with hematological malignancies". BMC Med. 10: 97. doi:10.1186/1741-7015-10-97. PMC 3482556. PMID 22931433.
  21. ↑ Cervantes GM, Cayci Z (May 2015). "Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author's Institution". J Clin Med. 4 (5): 1102–12. doi:10.3390/jcm4051102. PMC 4470219. PMID 26239467.
  22. ↑ Sharma A, Buxi G, Walia R, Yadav RB, Sharma S (2011). "Childhood acute erythroleukemia diagnosis by flow cytometry". Indian J Pathol Microbiol. 54 (1): 173–5. doi:10.4103/0377-4929.77395. PMID 21393910.
  23. ↑ Atkinson J, Hrisinko MA, Weil SC (December 1992). "Erythroleukemia: a review of 15 cases meeting 1985 FAB criteria and survey of the literature". Blood Rev. 6 (4): 204–14. PMID 1486289.
  24. ↑ 24.0 24.1 Almeida AM, Prebet T, Itzykson R, Ramos F, Al-Ali H, Shammo J, Pinto R, Maurillo L, Wetzel J, Musto P, Van De Loosdrecht AA, Costa MJ, Esteves S, Burgstaller S, Stauder R, Autzinger EM, Lang A, Krippl P, Geissler D, Falantes JF, Pedro C, Bargay J, Deben G, Garrido A, Bonanad S, Diez-Campelo M, Thepot S, Ades L, Sperr WR, Valent P, Fenaux P, Sekeres MA, Greil R, Pleyer L (April 2017). "Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study". Int J Mol Sci. 18 (4). doi:10.3390/ijms18040837. PMC 5412421. PMID 28420120.
  25. ↑ Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (February 2010). "Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia". J. Clin. Oncol. 28 (4): 562–9. doi:10.1200/JCO.2009.23.8329. PMID 20026804.
  26. ↑ Oran B, de Lima M (November 2011). "Prevention and treatment of acute myeloid leukemia relapse after allogeneic stem cell transplantation". Curr. Opin. Hematol. 18 (6): 388–94. doi:10.1097/MOH.0b013e32834b6158. PMID 21897227.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Erythroleukemia&oldid=1509042"